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Abstract
The prevalence of cutaneous and soft tissue zygomycosis appears to have increased in recent years. We reviewed 78 case reports of
cutaneous zygomycosis published from 2004 through 2008. Most patients with cutaneous zygomycosis have underlying conditions such
as haematological malignancies, diabetes mellitus or solid organ transplantation, but a large proportion of them are immunocompetent.
Trauma is the most common predisposing factor leading to zygomycosis in immunocompetent patients. If the patient is immunocompro-
mised, the infection may disseminate. Cutaneous zygomycosis may be localized, may extend to deep underlying tissues, or may be
disseminated. The most common clinical presentation is induration of the skin with surrounding erythema, rapidly progressing to necro-
sis. Histological examination and culture of soft tissue are important for the diagnosis of cutaneous zygomycosis. Treatment consists of
surgical debridement, administration of antifungal agents (amphotericin B formulations and/or posaconazole) and, occasionally,
hyperbaric oxygen. Mortality rates are approximately 30%.
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Introduction
Zygomycosis has emerged as the third most common inva-
sive fungal infection after candidosis and aspergillosis. It con-
stitutes a group of infections caused by members of the class
Zygomycetes, which is divided into two orders, Mucorales
and Entomophthorales [1]. Although zygomycosis can involve
any organ of the body, the most common clinical presenta-
tions are rhinocerebral, pulmonary, cutaneous and dissemi-
nated. The following is a review of cutaneous zygomycosis.
Epidemiology
The prevalence of cutaneous and soft tissue zygomycosis
appears to have increased in recent years. A review of 929
cases by Roden et al. [2] included 176 cases (19%) of cutane-
ous zygomycosis. We searched PubMed for case reports of
cutaneous zygomycosis published from 2004 through 2008 in
English, selecting only articles describing cases in which the
diagnosis had been conﬁrmed by histology and/or culture,
and identiﬁed 78 cases [3–65]. The large number of publica-
tions in recent years may reﬂect the greater awareness in
the part of physicians of this infection, as well as publication
bias, but there are also data which support an actual increase
in the incidence of zygomycosis, mainly in patients with hae-
matological malignancies [66]. In the review by Roden et al.,
cutaneous zygomycosis was the third most common clinical
form of zygomycosis, after rhinocerebral and pulmonary
forms [2]. In children, however, the skin is the most com-
mon site of infection with Zygomycetes [67]. In our review
of 78 cases, 22 (28%) patients were children (0–14 years)
and, of those, eight (36%) were £12 months old.
Most patients with cutaneous zygomycosis have underlying
conditions such as haematological malignancies, diabetes
mellitus or solid organ transplantation, but a large propor-
tion of them are immunocompetent. In a review by Adam
et al. [68], diabetes was present in only 26% of cutaneous
cases and leukaemia and/or neutropenia in 16%. In the
review by Roden et al. [2], of the 176 patients with cutane-
ous infections, 50% had no underlying conditions, whereas in
our review of 78 patients, 31 (40%) were immunocompetent,
18 (23%) had a haematological malignancy, 10 (13%) had
diabetes mellitus, ﬁve (6%) had received a solid organ
transplant, four (5%) had received corticosteroids, while the
remaining 10 (13%) had various other underlying diseases,
including metabolic acidosis due to ureteroileostomy, cirrho-
sis, prematurity, non-haematological malignancy, malnutrition
and HIV infection.
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Pathogenesis and Mode of Transmission
Zygomycetes can be acquired by inhalation, ingestion or
direct inoculation. In cutaneous zygomycosis, the latter is by
far the most common mode of transmission. A hallmark of
these infections is the presence of extensive angioinvasion
with resultant infarctions and tissue necrosis [69]. Intact
mucosal and endothelial barriers serve as structural defences
against tissue invasion and angioinvasion by Zygomycetes.
These barriers can be disrupted by trauma, prior infection,
cytotoxic chemotherapy, or maceration of skin by a moist
surface [58], allowing high loads of sporangiospores to invade
the dermis. The disease can be very invasive locally and can
penetrate from the cutaneous and subcutaneous tissues into
the adjacent fat, muscle, fascia and bone [69]. Depending on
the immune status of the host, the infection can then be hae-
matogenously disseminated to deep organs. There have been
cases where a trivial trauma, such as that caused by the use
of blood glucose self-monitoring equipment [55] or by a
plant thorn [70], has led to fatal disseminated disease.
Although dissemination from skin to other organs is rela-
tively common, the reverse (i.e. dissemination to the skin) is
very rare [69]. Roden et al. noted such reverse dissemination
in only six cases (3%) [2].
Insect bites [19], stings [1] and even pecking by birds [65]
have been implicated in disease transmission in cases of cuta-
neous and subcutaneous zygomycosis. Trauma in general is a
major cause of zygomycosis, especially in immunocompetent
patients. Besides the previously mentioned minor traumas,
road trafﬁc accidents [23,24,31,38,39] or crush injuries (by
agricultural machines) [29] can lead to traumatic implantation
of soil and subsequent zygomycosis. Zygomycosis has also
been reported to occur as a result of injury in a natural
disaster, such as the tsunami that struck Southeast Asia in
2004 [48] or the volcanic eruption which wiped out the
town of Armero, Colombia in 1985 [71]. Another well-
described cause of cutaneous zygomycosis is major burn
injury, which, in addition to disrupting the skin barriers, con-
fers signiﬁcant immunosuppression of variable duration
[5,46,52]. An increased risk for developing zygomycosis in
the burn patient is the development of a condition called
‘burned stress pseudodiabetes’, which is marked by the
occurrence of persistent hyperglycaemia and glucosuria [1].
In recent decades, zygomycosis has also emerged as a nos-
ocomial infection. In our review, 28 (36%) of 78 patients had
a hospital-acquired zygomycosis (Table 1). This type of zygo-
mycosis has been associated with iatrogenic immuno-
suppression and a variety of medical devices or procedures,
including antifungal prophylaxis, bandages [46], medication
patches [70], and intravenous [33,41–43] or arterial [45]
catheters. An outbreak of cutaneous Rhizopus arrhizus infec-
tion associated with karaya ostomy bags has been reported
[35]. Karaya gum, a product derived from the sap of the Ster-
culia urens tree, was utilized to make the non-sterile adhesive
of the ostomy bag used to afﬁx the pouch to the abdominal
surface.
Clinical Presentation
Cutaneous zygomycosis is subcategorized into three groups
[2]. Patients in whom the infection is conﬁned to the cutane-
ous or subcutaneous tissue are deﬁned as having localized
disease. Patients with invasion into muscle, tendon or bone
are classiﬁed as having deep extension of infection and
patients with cutaneous disease involving another non-contig-
uous site are deﬁned as having disseminated infection. In Ro-
den et al., 96 (56%) infections were localized, 43 (24%) were
accompanied by deep extension and 35 (20%) were dissemi-
nated [2]. In cases occurring after 2003, equivalent numbers
were 23 (32%), 38 (52%) and 12 (16%), respectively. Five
cases were not included because the clinical presentation
was not well described. In our review of 78 cases we found
no dissemination from an internal organ to the skin.
Any area of the skin can be affected by zygomycosis.
Although the upper and lower extremities are more often
involved, there have been reports of cutaneous zygomycosis
of the scalp [28,70], face [6,7,17,27], breast [18], thorax
[37], back [23], abdomen [22,36], gluteal area [47] and peri-
neum [42].
The clinical presentation of cutaneous zygomycosis varies.
The disease may be gradual in onset and slowly progressive
[54], or it may be fulminant, leading to gangrene and haema-
togenous dissemination [37,55]. In a report of cutaneous
TABLE 1. Mode of transmission of cutaneous zygo-
mycosis in case reports published before and after 2004.







Penetrating traumas 60 (34%) 31 (40%)a
Dressings 26 (15%) 6 (8%)
Surgery 26 (15%) 6 (8%)
Burns 11 (6%) 7 (9%)
Motor vehicle accidents 5 (3%) 8 (10%)
Falls 5 (3%) 2 (2%)
Not well described 42 (24%) 18 (23%)
aOf the 31 cases of penetrating trauma, 17 (55%) were nosocomial, related to
intravenous, arterial or other catheters or needles.
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zygomycosis caused by Mucor hiemalis in an immunocompe-
tent child, the disease manifested as superﬁcial lesions with
only slightly elevated circinate and squamous borders resem-
bling tinea corporis and was not diagnosed for 5 years [54].
Rubin et al. [45] described a case of superﬁcial zygomycosis
caused by Rhizopus arrhizus, which consisted of targetoid pla-
ques with outer erythematous rims and echymotic or black-
ened necrotic centres; the authors suggested the name
‘bull’s eye infarct of cutaneous zygomycosis’. Similar descrip-
tions have been reported by three other authors since 2003,
for infections caused by Cunninghamella bertholletiae in one
case and Rhizopus sp. in the other two [25, 32,44]. The dif-
ferential diagnosis of targetoid cutaneous lesions includes
multiple autoimmune diseases, drug reactions, infections,
inﬁltrative diseases, neoplastic disorders, and primary skin
diseases. In patients with open wounds, mucormycoses may
have a cotton-like appearance resembling that of bread
mould [21,39,57].
At the other end of the spectrum of clinical manifestations
of cutaneous zygomycosis are necrotizing fasciitis and gan-
grene. In such cases, the infection may initially have the form
of induration, blisters, pustules or necrotic ulcerations; it may
rapidly progress, forming cutaneous abscess and necrosis of
the deep subcutaneous tissues [12,29,57]. The lesions may
mimic pyoderma gangrenosum [60], bacterial synergistic gan-
grene, or other infections produced by Pseudomonas, Aspergil-
lus, Histoplasma, etc. When the disease is disseminated, the
patient shows the general signs and symptoms of sepsis.
Diagnosis
Early diagnosis of zygomycosis is essential to improve the
outcome. A necrotic lesion in an immunocompromised host
should raise suspicion of zygomycosis. In a patient who has
sustained a trauma, even if he or she is immunocompetent,
zygomycosis should be included in the differential diagnosis,
especially if there are necrotic elements, if the wound con-
tinues to expand despite broad-spectrum antibiotic therapy,
or if a mould is observed on the wound edges. Biopsy of the
lesions for histology and culture are necessary to establish
the diagnosis. The biopsy specimen should be taken from the
centre of the lesion and include subcutaneous fat, because
moulds frequently invade blood vessels of the dermis and
subcutis, resulting in an ischaemic cone at the skin surface
[72]. Impression smears from the wound edges may also
help in the diagnosis. Zygomycetes are characterized by
broad, mostly aseptate hyphae, with irregular branching that
occasionally occurs at right angles. The identiﬁcation of
Zygomycetes at the genus and species levels requires culture
studies. However, in a high proportion of cases cultures do
not yield a fungus. Cultures are negative in approximately
50% of cases of zygomycosis, including all sites of infection
[2]. In our review of cases of cutaneous zygomycosis after
2003, 56 (72%) of 78 reported cases had a positive culture.
The majority were Rhizopus spp. (24/56, 43%). The other iso-
lates were Absidia corymbifera (12/56, 21%), Apophysomyces
elegans (6/56, 11%), Mucor spp. (3/56, 5%), Rhizomucor spp.
(3/56, 5%), Cunninghamella bertholletiae (3/56, 5%) and Sakse-
nae vasiformis (4/56, 7%), and in one case the culture showed
Mucorales. Recently, molecular methods have begun to be
used in the diagnosis of zygomycosis; these may be very use-
ful as an adjunctive diagnostic tool, especially in cases of sus-
pected outbreaks [72].
Treatment and Outcome
Extensive surgical debridement in conjunction with systemic
antifungal medication is the standard treatment of cutaneous
zygomycosis. Surgical debridement consists of complete
resection of necrotic and infected tissue, often with a cuff of
apparently uninfected tissue. The wound must be closely
monitored and at the ﬁrst indication of disease progression,
surgery must be repeated. In a series of zygomycoses in the
upper extremities, patients underwent an average of ten
surgical debridements (ranging from four to 20) [31]. Ampu-
tation is often necessary when the affected area is an extrem-
ity [5,31]. In cases of zygomycosis of the face, the operations
may be disﬁguring, necessitating plastic reconstruction.
Amphotericin B (AmB) is used for the treatment of zygo-
mycosis. Liposomal AmB and other lipid formulations are
widely used and allow the administration of higher doses (5–
7 mg/kg) [69]. Posaconazole has recently been used success-
fully as salvage therapy for zygomycosis [39].
The prognosis in cutaneous zygomycosis is better than
that in the other clinical forms of the disease, but mortality
still remains at 31% [2]. Roden et al. found mortality rates of
10% in localized infection, 26% in cutaneous zygomycosis
with deep extension and 94% in disseminated disease. In our
review, the overall mortality rate was 30%, and speciﬁc rates
were 4%, 29% and 83% in localized, extended and dissemi-
nated disease, respectively.
Conclusions
In summary, a high index of suspicion and early and aggres-
sive management, making use of all available modalities, may
improve the outcome of zygomycosis.
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